Annual EBITDA
-$51.89 M
-$9.82 M-23.33%
31 December 2023
Summary:
Aptose Biosciences annual earnings before interest, taxes, depreciation & amortization is currently -$51.89 million, with the most recent change of -$9.82 million (-23.33%) on 31 December 2023. During the last 3 years, it has risen by +$3.26 million (+5.92%). APTO annual EBITDA is now -458.10% below its all-time high of $14.49 million, reached on 31 May 2003.APTO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$6.87 M
+$374.00 K+5.16%
30 September 2024
Summary:
Aptose Biosciences quarterly earnings before interest, taxes, depreciation & amortization is currently -$6.87 million, with the most recent change of +$374.00 thousand (+5.16%) on 30 September 2024. Over the past year, it has increased by +$4.70 million (+40.63%). APTO quarterly EBITDA is now -247.29% below its all-time high of $4.66 million, reached on 31 May 2003.APTO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$35.78 M
+$4.70 M+11.61%
30 September 2024
Summary:
Aptose Biosciences TTM earnings before interest, taxes, depreciation & amortization is currently -$35.78 million, with the most recent change of +$4.70 million (+11.61%) on 30 September 2024. Over the past year, it has increased by +$14.40 million (+28.69%). APTO TTM EBITDA is now -1286.10% below its all-time high of $3.02 million, reached on 31 May 2003.APTO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.3% | +40.6% | +28.7% |
| 3 y3 years | +5.9% | +38.7% | +35.2% |
| 5 y5 years | -78.8% | +0.1% | -44.2% |
APTO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -23.3% | +19.9% | at high | +71.6% | at high | +44.8% |
| 5 y | 5 years | -97.7% | +19.9% | at high | +71.6% | -44.2% | +44.8% |
| alltime | all time | -458.1% | +19.9% | -247.3% | +71.6% | -1286.1% | +44.8% |
Aptose Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.87 M(-5.2%) | -$35.78 M(-11.6%) |
| June 2024 | - | -$7.24 M(-25.0%) | -$40.48 M(-14.9%) |
| Mar 2024 | - | -$9.65 M(-19.7%) | -$47.58 M(-8.3%) |
| Dec 2023 | -$51.89 M(+23.3%) | -$12.02 M(+3.9%) | -$51.89 M(+3.4%) |
| Sept 2023 | - | -$11.57 M(-19.3%) | -$50.18 M(+3.5%) |
| June 2023 | - | -$14.34 M(+2.7%) | -$48.49 M(+8.5%) |
| Mar 2023 | - | -$13.96 M(+35.5%) | -$44.69 M(+6.2%) |
| Dec 2022 | -$42.07 M(-35.1%) | -$10.30 M(+4.2%) | -$42.07 M(-24.8%) |
| Sept 2022 | - | -$9.88 M(-6.1%) | -$55.96 M(-2.3%) |
| June 2022 | - | -$10.53 M(-7.2%) | -$57.27 M(-4.7%) |
| Mar 2022 | - | -$11.35 M(-53.1%) | -$60.08 M(-7.3%) |
| Dec 2021 | -$64.83 M(+17.5%) | -$24.18 M(+115.9%) | -$64.83 M(+17.3%) |
| Sept 2021 | - | -$11.20 M(-16.0%) | -$55.24 M(-3.4%) |
| June 2021 | - | -$13.34 M(-17.2%) | -$57.18 M(-4.0%) |
| Mar 2021 | - | -$16.10 M(+10.2%) | -$59.58 M(+8.0%) |
| Dec 2020 | -$55.15 M(+110.2%) | -$14.61 M(+11.1%) | -$55.15 M(+14.2%) |
| Sept 2020 | - | -$13.14 M(-16.5%) | -$48.28 M(+14.9%) |
| June 2020 | - | -$15.73 M(+34.7%) | -$42.02 M(+29.4%) |
| Mar 2020 | - | -$11.68 M(+51.0%) | -$32.48 M(+23.7%) |
| Dec 2019 | -$26.24 M(-9.6%) | -$7.73 M(+12.4%) | -$26.24 M(+5.8%) |
| Sept 2019 | - | -$6.88 M(+11.2%) | -$24.81 M(+5.5%) |
| June 2019 | - | -$6.19 M(+13.6%) | -$23.52 M(-14.9%) |
| Mar 2019 | - | -$5.45 M(-13.6%) | -$27.64 M(-4.8%) |
| Dec 2018 | -$29.02 M(+147.1%) | -$6.30 M(+12.9%) | -$29.02 M(+11.6%) |
| Sept 2018 | - | -$5.58 M(-45.9%) | -$26.01 M(+12.5%) |
| June 2018 | - | -$10.31 M(+51.0%) | -$23.12 M(+51.8%) |
| Mar 2018 | - | -$6.83 M(+107.3%) | -$15.23 M(+30.5%) |
| Dec 2017 | -$11.74 M(-17.1%) | -$3.29 M(+22.5%) | -$11.67 M(+1.8%) |
| Sept 2017 | - | -$2.69 M(+11.2%) | -$11.46 M(-3.4%) |
| June 2017 | - | -$2.42 M(-26.0%) | -$11.86 M(-13.9%) |
| Mar 2017 | - | -$3.27 M(+6.0%) | -$13.78 M(-3.5%) |
| Dec 2016 | -$14.16 M(+21.9%) | -$3.08 M(-0.2%) | -$14.27 M(-6.6%) |
| Sept 2016 | - | -$3.09 M(-28.7%) | -$15.29 M(+4.7%) |
| June 2016 | - | -$4.33 M(+15.0%) | -$14.60 M(+12.8%) |
| Mar 2016 | - | -$3.77 M(-8.1%) | -$12.95 M(+8.2%) |
| Dec 2015 | -$11.62 M(+74.7%) | -$4.10 M(+70.8%) | -$11.97 M(+52.1%) |
| Sept 2015 | - | -$2.40 M(-10.4%) | -$7.87 M(+43.9%) |
| June 2015 | - | -$2.68 M(-4.0%) | -$5.47 M(-17.2%) |
| Mar 2015 | - | -$2.79 M(-26.8%) | -$6.60 M(-30.5%) |
| Dec 2014 | -$6.65 M(-30.6%) | - | - |
| May 2014 | -$9.59 M(+79.0%) | -$3.81 M(+80.6%) | -$9.50 M(+37.2%) |
| Feb 2014 | - | -$2.11 M(-17.7%) | -$6.92 M(+12.7%) |
| Nov 2013 | - | -$2.57 M(+154.9%) | -$6.14 M(+18.3%) |
| Aug 2013 | - | -$1.01 M(-18.8%) | -$5.19 M(-4.6%) |
| May 2013 | -$5.36 M(+21.3%) | -$1.24 M(-6.8%) | -$5.44 M(+8.1%) |
| Feb 2013 | - | -$1.33 M(-17.6%) | -$5.03 M(+6.7%) |
| Nov 2012 | - | -$1.61 M(+28.6%) | -$4.71 M(+4.7%) |
| Aug 2012 | - | -$1.26 M(+51.3%) | -$4.50 M(+2.8%) |
| May 2012 | -$4.42 M(-11.7%) | -$829.70 K(-18.2%) | -$4.38 M(-5.8%) |
| Feb 2012 | - | -$1.01 M(-27.6%) | -$4.65 M(-10.6%) |
| Nov 2011 | - | -$1.40 M(+23.6%) | -$5.20 M(+5.3%) |
| Aug 2011 | - | -$1.13 M(+3.3%) | -$4.94 M(+1.6%) |
| May 2011 | -$5.00 M | -$1.10 M(-29.9%) | -$4.86 M(-12.7%) |
| Feb 2011 | - | -$1.57 M(+37.5%) | -$5.57 M(+5.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2010 | - | -$1.14 M(+8.1%) | -$5.26 M(-0.5%) |
| Aug 2010 | - | -$1.05 M(-41.6%) | -$5.29 M(+0.4%) |
| May 2010 | -$5.31 M(-17.0%) | -$1.81 M(+43.4%) | -$5.26 M(-1.4%) |
| Feb 2010 | - | -$1.26 M(+8.1%) | -$5.34 M(-4.4%) |
| Nov 2009 | - | -$1.17 M(+13.0%) | -$5.58 M(-3.8%) |
| Aug 2009 | - | -$1.03 M(-45.2%) | -$5.80 M(-14.1%) |
| May 2009 | -$6.40 M(-40.3%) | -$1.88 M(+24.9%) | -$6.75 M(-15.4%) |
| Feb 2009 | - | -$1.51 M(+8.7%) | -$7.98 M(-18.9%) |
| Nov 2008 | - | -$1.39 M(-30.2%) | -$9.84 M(-10.6%) |
| Aug 2008 | - | -$1.98 M(-36.2%) | -$11.01 M(+4.5%) |
| May 2008 | -$10.71 M(+64.0%) | -$3.11 M(-7.7%) | -$10.54 M(+17.1%) |
| Feb 2008 | - | -$3.37 M(+32.0%) | -$9.00 M(+28.9%) |
| Nov 2007 | - | -$2.55 M(+68.8%) | -$6.98 M(+6.6%) |
| Aug 2007 | - | -$1.51 M(-3.8%) | -$6.54 M(-2.3%) |
| May 2007 | -$6.53 M(-49.3%) | -$1.57 M(+16.3%) | -$6.70 M(-5.8%) |
| Feb 2007 | - | -$1.35 M(-36.2%) | -$7.10 M(-16.9%) |
| Nov 2006 | - | -$2.12 M(+27.3%) | -$8.55 M(-15.2%) |
| Aug 2006 | - | -$1.66 M(-16.0%) | -$10.08 M(-19.8%) |
| May 2006 | -$12.88 M(-17.2%) | -$1.98 M(-29.2%) | -$12.57 M(-5.8%) |
| Feb 2006 | - | -$2.79 M(-23.4%) | -$13.34 M(-6.6%) |
| Nov 2005 | - | -$3.65 M(-12.1%) | -$14.29 M(-5.6%) |
| Aug 2005 | - | -$4.15 M(+50.9%) | -$15.13 M(-2.0%) |
| May 2005 | -$15.55 M(-28.0%) | -$2.75 M(-26.5%) | -$15.43 M(-14.3%) |
| Feb 2005 | - | -$3.74 M(-16.7%) | -$18.00 M(-11.0%) |
| Nov 2004 | - | -$4.49 M(+0.9%) | -$20.21 M(+0.3%) |
| Aug 2004 | - | -$4.45 M(-16.3%) | -$20.14 M(-6.3%) |
| May 2004 | -$21.59 M(-249.0%) | -$5.32 M(-10.7%) | -$21.49 M(+86.7%) |
| Feb 2004 | - | -$5.95 M(+34.7%) | -$11.51 M(+392.6%) |
| Nov 2003 | - | -$4.42 M(-23.8%) | -$2.34 M(+758.0%) |
| Aug 2003 | - | -$5.80 M(-224.4%) | -$272.40 K(-109.0%) |
| May 2003 | $14.49 M(-288.0%) | $4.66 M(+44.8%) | $3.02 M(-176.2%) |
| Feb 2003 | - | $3.22 M(-236.8%) | -$3.96 M(-52.2%) |
| Nov 2002 | - | -$2.36 M(-6.2%) | -$8.28 M(+0.2%) |
| Aug 2002 | - | -$2.51 M(+8.8%) | -$8.27 M(+9.7%) |
| May 2002 | -$7.71 M(-17.8%) | -$2.31 M(+108.9%) | -$7.54 M(-17.0%) |
| Feb 2002 | - | -$1.11 M(-52.7%) | -$9.08 M(-5.5%) |
| Nov 2001 | - | -$2.34 M(+31.0%) | -$9.61 M(+0.3%) |
| Aug 2001 | - | -$1.78 M(-53.7%) | -$9.59 M(+1.5%) |
| May 2001 | -$9.37 M(+116.8%) | -$3.85 M(+135.7%) | -$9.44 M(+18.3%) |
| Feb 2001 | - | -$1.64 M(-29.2%) | -$7.98 M(+11.3%) |
| Nov 2000 | - | -$2.31 M(+41.0%) | -$7.17 M(+32.8%) |
| Aug 2000 | - | -$1.64 M(-31.6%) | -$5.40 M(+34.0%) |
| May 2000 | -$4.32 M(+44.9%) | -$2.39 M(+190.6%) | -$4.03 M(+75.4%) |
| Feb 2000 | - | -$824.00 K(+51.9%) | -$2.30 M(+4.4%) |
| Nov 1999 | - | -$542.30 K(+102.7%) | -$2.20 M(-1.9%) |
| Aug 1999 | - | -$267.60 K(-59.7%) | -$2.24 M(-19.8%) |
| May 1999 | -$2.98 M(-3.4%) | -$663.20 K(-8.8%) | -$2.80 M(-6.0%) |
| Feb 1999 | - | -$726.80 K(+24.4%) | -$2.97 M(+0.8%) |
| Nov 1998 | - | -$584.10 K(-29.0%) | -$2.95 M(-3.9%) |
| Aug 1998 | - | -$822.60 K(-2.2%) | -$3.07 M(+6.0%) |
| May 1998 | -$3.09 M(-1.0%) | -$840.90 K(+19.7%) | -$2.89 M(+41.0%) |
| Feb 1998 | - | -$702.60 K(-0.0%) | -$2.05 M(+52.0%) |
| Nov 1997 | - | -$702.70 K(+8.5%) | -$1.35 M(+108.5%) |
| Aug 1997 | - | -$647.90 K | -$647.90 K |
| May 1997 | -$3.12 M | - | - |
FAQ
- What is Aptose Biosciences annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Aptose Biosciences?
- What is Aptose Biosciences annual EBITDA year-on-year change?
- What is Aptose Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Aptose Biosciences?
- What is Aptose Biosciences quarterly EBITDA year-on-year change?
- What is Aptose Biosciences TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Aptose Biosciences?
- What is Aptose Biosciences TTM EBITDA year-on-year change?
What is Aptose Biosciences annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of APTO is -$51.89 M
What is the all time high annual EBITDA for Aptose Biosciences?
Aptose Biosciences all-time high annual earnings before interest, taxes, depreciation & amortization is $14.49 M
What is Aptose Biosciences annual EBITDA year-on-year change?
Over the past year, APTO annual earnings before interest, taxes, depreciation & amortization has changed by -$9.82 M (-23.33%)
What is Aptose Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of APTO is -$6.87 M
What is the all time high quarterly EBITDA for Aptose Biosciences?
Aptose Biosciences all-time high quarterly earnings before interest, taxes, depreciation & amortization is $4.66 M
What is Aptose Biosciences quarterly EBITDA year-on-year change?
Over the past year, APTO quarterly earnings before interest, taxes, depreciation & amortization has changed by +$4.70 M (+40.63%)
What is Aptose Biosciences TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of APTO is -$35.78 M
What is the all time high TTM EBITDA for Aptose Biosciences?
Aptose Biosciences all-time high TTM earnings before interest, taxes, depreciation & amortization is $3.02 M
What is Aptose Biosciences TTM EBITDA year-on-year change?
Over the past year, APTO TTM earnings before interest, taxes, depreciation & amortization has changed by +$14.40 M (+28.69%)